MedPath

Vinorelbine in Treating Older Women With Stage IV Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
Interventions
Registration Number
NCT00022152
Lead Sponsor
Alliance for Clinical Trials in Oncology
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of vinorelbine in treating older women who have stage IV breast cancer.

Detailed Description

OBJECTIVES:

* Determine the objective response rate in elderly women with stage IV breast cancer treated with oral vinorelbine.

* Determine the toxicity profile of this drug in these patients.

* Determine the time to progression in patients treated with this drug.

* Determine the quality of life of patients treated with this drug.

* Assess individual variation in responses (toxicity and/or activity), pharmacokinetic parameters, and/or biologic correlates due to genetic differences in enzymes involved in the transport, metabolism, and/or mechanism of action of this drug in these patients.

OUTLINE: Patients receive oral vinorelbine once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline and then after completion of the second course.

Patients are followed every 3 months for 5 years.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
25
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
vinorelbinevinorelbine tartratePatients receive oral vinorelbine once weekly. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then after completion of the second course. Patients are followed every 3 months for 5 years.
Primary Outcome Measures
NameTimeMethod
objective response rateUp to 5 years
Secondary Outcome Measures
NameTimeMethod
time to progressionUp to 5 years
quality of lifeUp to 5 years

Trial Locations

Locations (18)

CCOP - Duluth

🇺🇸

Duluth, Minnesota, United States

Altru Health Systems

🇺🇸

Grand Forks, North Dakota, United States

CentraCare Health Plaza

🇺🇸

Saint Cloud, Minnesota, United States

CCOP - Geisinger Clinic and Medical Center

🇺🇸

Danville, Pennsylvania, United States

CCOP - Illinois Oncology Research Association

🇺🇸

Peoria, Illinois, United States

CCOP - Scottsdale Oncology Program

🇺🇸

Scottsdale, Arizona, United States

CCOP - Cedar Rapids Oncology Project

🇺🇸

Cedar Rapids, Iowa, United States

CCOP - Carle Cancer Center

🇺🇸

Urbana, Illinois, United States

CCOP - Iowa Oncology Research Association

🇺🇸

Des Moines, Iowa, United States

CCOP - Wichita

🇺🇸

Wichita, Kansas, United States

CCOP - Metro-Minnesota

🇺🇸

Saint Louis Park, Minnesota, United States

Medcenter One Health System

🇺🇸

Bismarck, North Dakota, United States

CCOP - Sioux Community Cancer Consortium

🇺🇸

Sioux Falls, South Dakota, United States

Rapid City Regional Hospital

🇺🇸

Rapid City, South Dakota, United States

CCOP - Ann Arbor Regional

🇺🇸

Ann Arbor, Michigan, United States

Mayo Clinic Cancer Center

🇺🇸

Rochester, Minnesota, United States

CCOP - Missouri Valley Cancer Consortium

🇺🇸

Omaha, Nebraska, United States

Siouxland Hematology-Oncology

🇺🇸

Sioux City, Iowa, United States

© Copyright 2025. All Rights Reserved by MedPath